Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895846919> ?p ?o ?g. }
- W2895846919 endingPage "2347" @default.
- W2895846919 startingPage "2341" @default.
- W2895846919 abstract "In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD).Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA).A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059).The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit." @default.
- W2895846919 created "2018-10-26" @default.
- W2895846919 creator A5003405177 @default.
- W2895846919 creator A5004047083 @default.
- W2895846919 creator A5008007308 @default.
- W2895846919 creator A5011410319 @default.
- W2895846919 creator A5011919158 @default.
- W2895846919 creator A5016987068 @default.
- W2895846919 creator A5017728105 @default.
- W2895846919 creator A5023482492 @default.
- W2895846919 creator A5024741688 @default.
- W2895846919 creator A5032626301 @default.
- W2895846919 creator A5033698551 @default.
- W2895846919 creator A5036531617 @default.
- W2895846919 creator A5038489675 @default.
- W2895846919 creator A5041593789 @default.
- W2895846919 creator A5042362865 @default.
- W2895846919 creator A5042391571 @default.
- W2895846919 creator A5043793453 @default.
- W2895846919 creator A5056688392 @default.
- W2895846919 creator A5056873538 @default.
- W2895846919 creator A5057181684 @default.
- W2895846919 creator A5069170386 @default.
- W2895846919 creator A5069307550 @default.
- W2895846919 creator A5072039363 @default.
- W2895846919 creator A5073939473 @default.
- W2895846919 creator A5085341927 @default.
- W2895846919 creator A5085853437 @default.
- W2895846919 creator A5087559224 @default.
- W2895846919 creator A5089392438 @default.
- W2895846919 date "2018-12-01" @default.
- W2895846919 modified "2023-10-01" @default.
- W2895846919 title "Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto" @default.
- W2895846919 cites W1583886228 @default.
- W2895846919 cites W1929478668 @default.
- W2895846919 cites W2014750426 @default.
- W2895846919 cites W2086064725 @default.
- W2895846919 cites W2096745115 @default.
- W2895846919 cites W2105265201 @default.
- W2895846919 cites W2105496345 @default.
- W2895846919 cites W2106777108 @default.
- W2895846919 cites W2109772731 @default.
- W2895846919 cites W2142460765 @default.
- W2895846919 cites W2145896038 @default.
- W2895846919 cites W2295085830 @default.
- W2895846919 cites W2394773016 @default.
- W2895846919 cites W2734897937 @default.
- W2895846919 cites W2751912349 @default.
- W2895846919 cites W2779944044 @default.
- W2895846919 cites W2788106879 @default.
- W2895846919 cites W2801956643 @default.
- W2895846919 cites W2803428420 @default.
- W2895846919 cites W2807037141 @default.
- W2895846919 cites W373117725 @default.
- W2895846919 doi "https://doi.org/10.1093/annonc/mdy460" @default.
- W2895846919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30335131" @default.
- W2895846919 hasPublicationYear "2018" @default.
- W2895846919 type Work @default.
- W2895846919 sameAs 2895846919 @default.
- W2895846919 citedByCount "187" @default.
- W2895846919 countsByYear W28958469192018 @default.
- W2895846919 countsByYear W28958469192019 @default.
- W2895846919 countsByYear W28958469192020 @default.
- W2895846919 countsByYear W28958469192021 @default.
- W2895846919 countsByYear W28958469192022 @default.
- W2895846919 countsByYear W28958469192023 @default.
- W2895846919 crossrefType "journal-article" @default.
- W2895846919 hasAuthorship W2895846919A5003405177 @default.
- W2895846919 hasAuthorship W2895846919A5004047083 @default.
- W2895846919 hasAuthorship W2895846919A5008007308 @default.
- W2895846919 hasAuthorship W2895846919A5011410319 @default.
- W2895846919 hasAuthorship W2895846919A5011919158 @default.
- W2895846919 hasAuthorship W2895846919A5016987068 @default.
- W2895846919 hasAuthorship W2895846919A5017728105 @default.
- W2895846919 hasAuthorship W2895846919A5023482492 @default.
- W2895846919 hasAuthorship W2895846919A5024741688 @default.
- W2895846919 hasAuthorship W2895846919A5032626301 @default.
- W2895846919 hasAuthorship W2895846919A5033698551 @default.
- W2895846919 hasAuthorship W2895846919A5036531617 @default.
- W2895846919 hasAuthorship W2895846919A5038489675 @default.
- W2895846919 hasAuthorship W2895846919A5041593789 @default.
- W2895846919 hasAuthorship W2895846919A5042362865 @default.
- W2895846919 hasAuthorship W2895846919A5042391571 @default.
- W2895846919 hasAuthorship W2895846919A5043793453 @default.
- W2895846919 hasAuthorship W2895846919A5056688392 @default.
- W2895846919 hasAuthorship W2895846919A5056873538 @default.
- W2895846919 hasAuthorship W2895846919A5057181684 @default.
- W2895846919 hasAuthorship W2895846919A5069170386 @default.
- W2895846919 hasAuthorship W2895846919A5069307550 @default.
- W2895846919 hasAuthorship W2895846919A5072039363 @default.
- W2895846919 hasAuthorship W2895846919A5073939473 @default.
- W2895846919 hasAuthorship W2895846919A5085341927 @default.
- W2895846919 hasAuthorship W2895846919A5085853437 @default.
- W2895846919 hasAuthorship W2895846919A5087559224 @default.
- W2895846919 hasAuthorship W2895846919A5089392438 @default.
- W2895846919 hasBestOaLocation W28958469191 @default.
- W2895846919 hasConcept C121608353 @default.
- W2895846919 hasConcept C126322002 @default.